HC Wainwright Rates REGENXBIO (RGNX) buy, $26 Price Target

HC Wainwright keeps a bullish stance on the biotech firm as other Wall Street shops update their targets, a 150.24% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 3:03 AM EDT · Updated Jun 27, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated REGENXBIO Inc. ($RGNX) "buy" with a $26 price target on June 24, 2026.

Since the rating, $RGNX is up 31.3% after 1 week, down 2.4% after 1 month and down 30.6% to date (from the $9.97 close on Jun 24, 2026).

RGNX REGENXBIO Inc.

$6.92 -49.01% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright analyst Yi Chen reiterated a buy rating on REGENXBIO Inc. RGNX with a $26.00 price target on June 24, 2026.
HC Wainwright's $26 price target implies 150.24% upside from REGENXBIO Inc.'s ($RGNX) current $10.39 share price.
The stock traded around $10.39 on Friday, moving within a 52-week range of $5.46 to $16.19.
Wall Street sentiment includes a mix of updates, such as Mizuho initiating coverage with an outperform rating and a $22.00 target on October 5, 2026.

Get $RGNX trade alerts by text

We text you when insiders, Congress or big funds trade $RGNX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated REGENXBIO Inc. alert may contain errors. Disclosures

HC Wainwright Stays Bullish on REGENXBIO

HC Wainwright and its analyst Yi Chen kept an optimistic view on REGENXBIO Inc. (NasdaqGS: RGNX) by reiterating a buy rating and a $26.00 price target on June 24, 2026. This call places the firm's outlook well above where the shares currently trade, giving investors a look at how one long-standing supporter views the biotech company's pipeline potential.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +49.98% hypothetical

All-time return +149.69% S&P 500 +26.90%

vs. S&P 500 +122.79% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

How Wall Street Views the Stock

Other research firms have also adjusted their expectations for REGENXBIO through recent months. On June 22, 2026, Baird maintained an outperform rating while lifting its target to $32.00 from $27.00, and Leerink Partners kept an outperform rating with an 18.00 target. Later in the summer, on August 7, 2026, Barclays shifted its stance by downgrading the stock to an equal-weight rating with a $12.00 target. Shortly after, on August 10, 2026, HC Wainwright adjusted its own target to $23.00 while keeping a buy rating, followed by Baird maintaining an outperform rating with a $29.00 target and HC Wainwright maintaining a buy with a $21.00 target on August 25, 2026. Most recently, Mizuho initiated coverage on October 5, 2026, with an outperform rating and a $22.00 price target.

12-month forecast

$RGNX price target

REGENXBIO Inc. daily closes and this analyst's $26 target. Not advice.

Stock Price and Market Context

REGENXBIO shares changed hands at $10.39 on Friday. The company has a market capitalization of roughly $520.2 million. Because the company is still advancing its clinical-stage treatments, it does not currently carry a positive forward P/E ratio, sitting at -2.62.

What REGENXBIO Does

REGENXBIO Inc. is a biotechnology company based in Rockville, Maryland, focusing on gene therapies that deliver functional genes to cells with genetic defects. The company uses its proprietary adeno-associated virus gene delivery platform, known as the NAV Technology Platform, to build treatments. Its pipeline addresses various conditions, including wet age-related macular degeneration, diabetic retinopathy, Duchenne muscular dystrophy, and mucopolysaccharidosis types I and II. The firm also partners with larger drug developers like AbbVie Global Enterprises and Nippon Shinyaku to advance and commercialize these therapies outside the United States.

What's Ahead for RGNX

Investors tracking REGENXBIO will likely focus on the company's clinical trial updates and its upcoming financial disclosures. The firm is scheduled to release its next round of earnings results around November 5, 2026, which will offer fresh details on its financial standing and cash runway.